| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary molecular targets of 3,5-dichlorophenylboronic acid are not specific biological receptors but rather chemical functionalities such as diols and nucleophiles in biomolecules. In pharmaceutical research, compounds synthesized using this boronic acid have shown potent inhibitory activity against p38 MAP kinase, with the 3,5-dichloro substitution pattern being a key structural feature for achieving high potency and selectivity. The compound interacts with target proteins through the formation of reversible covalent bonds, which enhances the efficacy of inhibitors developed for specific cancer cell lines. Its ability to form stable boron-carbon and boron-oxygen bonds underpins its utility in both chemical synthesis and biological applications.
|
|---|---|
| ln Vitro |
In vitro, 3,5-dichlorophenylboronic acid functions primarily as a chemical reagent rather than a direct pharmacological agent. It has been utilized in the synthesis of inhibitors that demonstrate activity against specific cancer cell lines through the formation of stable complexes with target proteins. The compound exhibits the ability to selectively bind to diols, making it a valuable tool for studying carbohydrate recognition and glycoprotein interactions in cell-free systems. Its biochemical activity is largely attributed to its boronic acid functionality, which enables reversible covalent interactions with biological molecules containing diol or other nucleophilic groups.
|
| ln Vivo |
In vivo studies of 3,5-dichlorophenylboronic acid as a standalone compound are limited, as it is primarily used as a synthetic intermediate or biochemical reagent rather than a therapeutic agent. However, pharmaceutical compounds synthesized using this boronic acid derivative have been investigated for their anticancer properties and other therapeutic applications. The compound's ability to participate in various chemical reactions crucial for creating complex therapeutic agents suggests potential for in vivo efficacy when incorporated into drug molecules. Its application in developing biosensors and drug delivery systems further indicates indirect in vivo relevance.
|
| Enzyme Assay |
Typical in vitro enzyme/receptor binding assays for boronic acid derivatives like 3,5-dichlorophenylboronic acid involve evaluating their interaction with diol-containing biomolecules such as glycoproteins and carbohydrates. The assay generally includes incubating the compound with the target molecule in a suitable buffer system (e.g., PBS or HEPES, pH 7.4) at room temperature or 37°C for 30 minutes to several hours. Binding affinity is commonly assessed using techniques such as fluorescence spectroscopy, surface plasmon resonance, or isothermal titration calorimetry. The reversible covalent bond formation between the boronic acid and cis-diol groups can be monitored by changes in absorbance or fluorescence signals, with detection limits typically in the micromolar to millimolar range.
|
| Cell Assay |
Cellular assays for 3,5-dichlorophenylboronic acid typically involve treating cancer cell lines with the compound or its derivatives to evaluate antiproliferative effects. A standard protocol includes culturing cells (e.g., HeLa, MCF-7, or A549) in appropriate media (DMEM or RPMI-1640 with 10% FBS) at 37°C in 5% CO₂. Cells are seeded in 96-well plates and incubated with varying concentrations of the compound (typically 0.1-100 μM) for 24-72 hours. Cell viability is then assessed using MTT, CCK-8, or SRB assays, with IC₅₀ values calculated from dose-response curves. The compound's ability to form stable complexes with target proteins enhances the efficacy of these inhibitors in cellular models.
|
| Animal Protocol |
In vivo animal studies for compounds derived from 3,5-dichlorophenylboronic acid typically use murine xenograft models to evaluate anticancer efficacy. A common protocol involves subcutaneous implantation of cancer cells (e.g., 5×10⁶ cells) into immunodeficient mice (6-8 weeks old, female BALB/c nude mice). Once tumors reach approximately 100-200 mm³, animals are randomized into treatment and control groups (n=6-10 per group). Test compounds are administered via oral gavage, intraperitoneal injection, or intravenous injection at doses ranging from 10-100 mg/kg, typically daily or every other day for 2-4 weeks. Tumor volume and body weight are monitored every 2-3 days, with endpoints including tumor growth inhibition, survival analysis, and histopathological examination.
|
| ADME/Pharmacokinetics |
As a chemical reagent rather than a drug candidate, comprehensive pharmacokinetic data for 3,5-dichlorophenylboronic acid is limited. However, boronic acid derivatives generally exhibit moderate oral bioavailability due to their polar nature and susceptibility to metabolic oxidation. The compound is a solid at room temperature with a molecular weight of 190.82 g/mol, which influences its absorption and distribution properties. In biological systems, boronic acids can form reversible complexes with proteins and other biomolecules, affecting their plasma protein binding and tissue distribution. The compound is typically stored as a powder at -20°C for long-term stability and is soluble in organic solvents such as DMSO and methanol.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3,5-dichlorophenylboronic acid is limited as it is primarily used as a research reagent. As a boronic acid derivative, it may exhibit moderate toxicity through interactions with biological nucleophiles and potential inhibition of proteasome activity. The compound is classified for research use only and not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. Acute toxicity studies in animal models would typically involve oral or intraperitoneal administration with observation periods of 14 days, though specific data for this compound is not readily available in the public domain.
|
| Additional Infomation |
3,5-Dichlorophenylboronic acid is a versatile biochemical reagent with the molecular formula C₆H₅BCl₂O₂ and a purity typically ≥97%. It is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. The compound is commonly used as a sulfonylation reagent for organic synthesis and drug discovery. Its 3,5-dichloro substitution pattern on the phenyl ring is often a key structural feature for achieving high potency and selectivity in kinase inhibitor development. The compound is available in various pack sizes from multiple commercial suppliers and is typically stored at room temperature or 4°C in a dry, airtight container. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C6H5BCL2O2
|
|---|---|
| Molecular Weight |
190.82
|
| Exact Mass |
189.975
|
| CAS # |
67492-50-6
|
| PubChem CID |
2734331
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
351.7±52.0 °C at 760 mmHg
|
| Melting Point |
315 °C
|
| Flash Point |
166.5±30.7 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
2.79
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
124
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C(C([H])=C(B(O[H])O[H])C=1[H])Cl
|
| InChi Key |
DKYRKAIKWFHQHM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H5BCl2O2/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3,10-11H
|
| Chemical Name |
(3,5-dichlorophenyl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2405 mL | 26.2027 mL | 52.4054 mL | |
| 5 mM | 1.0481 mL | 5.2405 mL | 10.4811 mL | |
| 10 mM | 0.5241 mL | 2.6203 mL | 5.2405 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
